Grifols appoints Board member Steven Mayer as Executive Chair

– SPAIN, Barcelona –  Grifols (MCE: GRF | NASDAQ: GRFS) today announced the appointment of Steven Mayer as Executive Chair effective immediately, succeeding Victor Grifols Roura who retired but remained on the Board of Directors as Chairperson of Honor.

“We have also long admired Steven both for what he and his team accomplished at Talecris and for his insights and contributions while serving on our Board.  We are excited about introducing him to our broader team of world-class management and employees, and about working together with him to drive value for all constituents through a continued laser focus on our strategic plan, on operational execution, and on deleveraging our balance sheet.” said co-CEOs, Victor Grifols Deu and Raimon Grifols Roura.

Concurrently, Victor Grifols Roura will continue to be a member of Grifols’ Board of Directors and a valuable resource as a “proprietary director” and has also been appointed as Chairperson of Honor due to his invaluable contributions, steadfast leadership, and extraordinary dedication to the company.

About Steven F. Mayer

Mr. Mayer has extensive knowledge and experience in the healthcare sector and is well-acquainted with the plasma-derived protein therapeutics industry, having led the team that acquired and carved out Talecris Biotherapeutics from Bayer Healthcare, then grew the company’s revenues and employee base and dramatically improved its profitability and cash flow until its merger with Grifols in 2011, at which time he joined the Grifols Board. He has also served on boards of directors or equivalent bodies of over 30 other public and private companies in a variety of industries.  Before his 2018 retirement from Cerberus as Senior Managing Director, Co-Head of Global Private Equity, and Chairman of its Investment Committee, Mr. Mayer focused on opportunities to improve portfolio companies’ competitiveness and value through operational planning and execution as well as strategic initiatives and financial discipline.

Steven Mayer has served as director of Grifols, S.A. since January 2011. He is currently CEO of Iron Horse Acquisition Corp. and of Dedication Capital, LLC, private investment firms that he founded. From 2002 until 2018, he held various senior positions with Cerberus Capital Management, L.P. and Cerberus California, LLC, affiliated private investment firms, culminating with serving as Senior Managing Director, Co-Head of Global Private Equity, and Chairman of the Cerberus Investment Committee. He began his private equity career as a principal with Apollo Advisors, L.P. in 1992.

He holds a Bachelor of Arts degree, cum laude, from Princeton University and a Juris Doctor degree, magna cum laude, from Harvard Law School. He has taught courses at both those institutions and LUISS, a university in Rome.

Mr. Mayer has been a member of the Board of Directors or equivalent body of a large number of companies in a wide variety of industries in the U.S. and Europe. He is currently a member of the Board of Supervisors of Syntellix, AG, and a director of PrettyParty, LLC and 9Squared, LLC.

“I am thrilled to work alongside the Board, the co-CEOs, and the entire management team, using my expertise to help them achieve the company’s strategic goals and focus on operational excellence; sustainable growth in revenue, profitability, and cash flow; and strengthening the company’s balance sheet.  Of equal importance to me is ensuring that the company’s core values of integrity, respect, inclusion, and sustainability that Victor established and invariably adhered to, as well as its commitment to the health and wellbeing of patients worldwide, will continue to guide the company and its entire team going forward,” said Steven Mayer.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 and committed to improving the health and well-being of people around the world. Its three main business units – Biopharma, Diagnostic, and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 110 countries.
Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat rare, chronic, and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information, and services that enable hospitals, pharmacies, and healthcare professionals to efficiently deliver expert medical care.
Grifols, with more than 27,000 employees in more than 30 countries, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.
In 2021, Grifols’ economic impact in its core countries of operation was EUR 7.7 billion. The company also generated 141,500 jobs, including indirect and induced jobs.

For more information, please visit www.grifols.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.